Adult T-cell Leukemia/lymphoma - 89 Studies Found

Completed : 506U78 In Relapsed Or Refractory Acute Lymphoblastic Leukemia (T-ALL)
: T-ALL, T-NHL (Lymphoblastic)
: 2008-05-16
: Drug: Nelarabine 1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
Completed : A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
:
  • Adult T-cell Leukemia-Lymphoma
  • Peripheral T-cell Lymphoma

    • : 2010-07-22
    : Drug: Lenalidomide Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily o
Completed : A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL)
:
  • Adult T-cell Leukemia
  • Lymphoma

: 2005-09-01
:
  • Drug: VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis
Completed : Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
: Adult T-cell Leukemia-Lymphoma
: 2010-07-30
:
  • Drug: VCAP/AMP/VECP(mLSG15) VC
Terminated : Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma
:
  • Cutaneous T-Cell Lymphoma
  • Leukemia-Lymphoma, Adult T-Cell

: 2008-06-13
: Drug: Panobinostat (LBH589) 20mg/day p.o. on three times-a- week
Completed : Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
:
  • Leukemia, Adult T-Cell
  • HTLV I Associated T Cell Leukemia
  • <
    : 2016-02-20
    : Biological: IL-15 plus alemtuzumab rhIL-15 by s.c. injection Monday-Friday over two weeks; followed by a
Completed : Study of Adult T-Cell Leukemia/Lymphoma Among Carriers of HTLV-1
: Human T-Lymphoma Virus Type I
: 2006-06-19
Completed : Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
:
  • Adult T-Cell Leukemia and Lymphoma (ATL)
  • Adult Peripheral T-Cel
    : 2006-07-20
    : Drug: KW-0761 IV administration at 4 escalating dose levels.
Terminated : Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma
:
  • Lymphoma
  • Precancerous/Nonmalignant Condition

: 2009-02-28
:
  • Biological: PEG-interferon alfa-2b

Completed : Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma
: Acute T-Cell Leukemia-Lymphoma
: 2003-05-20
: Biological: Alemtuzumab Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 follo
<<< Previous | Next >>>